PL3250600T3 - Leczenie zaburzeń autoimmunologicznych przeciwciałami CD154 - Google Patents
Leczenie zaburzeń autoimmunologicznych przeciwciałami CD154Info
- Publication number
- PL3250600T3 PL3250600T3 PL15719675T PL15719675T PL3250600T3 PL 3250600 T3 PL3250600 T3 PL 3250600T3 PL 15719675 T PL15719675 T PL 15719675T PL 15719675 T PL15719675 T PL 15719675T PL 3250600 T3 PL3250600 T3 PL 3250600T3
- Authority
- PL
- Poland
- Prior art keywords
- antibodies
- treatment
- autoimmune disorders
- autoimmune
- disorders
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501613.2A GB201501613D0 (en) | 2015-01-30 | 2015-01-30 | Treatment of autoimmune disorders with CD154 antibodies |
| PCT/EP2015/059095 WO2016119909A1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
| EP15719675.9A EP3250600B1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3250600T3 true PL3250600T3 (pl) | 2020-09-21 |
Family
ID=52705552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15719675T PL3250600T3 (pl) | 2015-01-30 | 2015-04-27 | Leczenie zaburzeń autoimmunologicznych przeciwciałami CD154 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180022812A1 (pl) |
| EP (2) | EP3744735A1 (pl) |
| KR (1) | KR102543877B1 (pl) |
| CN (1) | CN107206075A (pl) |
| AU (2) | AU2015379642B2 (pl) |
| CA (1) | CA2975336C (pl) |
| CY (1) | CY1123116T1 (pl) |
| DK (1) | DK3250600T3 (pl) |
| ES (1) | ES2802982T3 (pl) |
| GB (1) | GB201501613D0 (pl) |
| HR (1) | HRP20201013T1 (pl) |
| HU (1) | HUE050024T2 (pl) |
| LT (1) | LT3250600T (pl) |
| PL (1) | PL3250600T3 (pl) |
| PT (1) | PT3250600T (pl) |
| RS (1) | RS60575B1 (pl) |
| RU (1) | RU2695443C2 (pl) |
| SI (1) | SI3250600T1 (pl) |
| WO (1) | WO2016119909A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012229236B2 (en) | 2011-03-11 | 2017-05-18 | Beth Israel Deaconess Medical Center, Inc. | Anti-CD40 antibodies and uses thereof |
| AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
| CN109073660B (zh) * | 2016-02-29 | 2022-10-28 | 麦恩泰科特有限公司 | 可用于治疗湿性年龄相关性黄斑变性的预测性标志物 |
| US20210317220A1 (en) * | 2018-09-24 | 2021-10-14 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN114895041A (zh) * | 2021-07-01 | 2022-08-12 | 浙江大学 | 一种检测抗蛋白酶体亚基α1-IgG抗体的试剂盒 |
| IL312829A (en) * | 2021-12-01 | 2024-07-01 | Biogen Ma Inc | Formulations containing FAB-PEG |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| EA019636B1 (ru) | 2007-03-22 | 2014-05-30 | Байоджен Айдек Ма Инк. | Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения |
| EP2367849B1 (en) * | 2008-12-05 | 2017-11-01 | ALS Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| AU2012249601A1 (en) | 2011-04-26 | 2013-05-09 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
-
2015
- 2015-01-30 GB GBGB1501613.2A patent/GB201501613D0/en not_active Ceased
- 2015-04-27 AU AU2015379642A patent/AU2015379642B2/en active Active
- 2015-04-27 SI SI201531299T patent/SI3250600T1/sl unknown
- 2015-04-27 HU HUE15719675A patent/HUE050024T2/hu unknown
- 2015-04-27 CA CA2975336A patent/CA2975336C/en active Active
- 2015-04-27 RS RS20200831A patent/RS60575B1/sr unknown
- 2015-04-27 US US15/547,223 patent/US20180022812A1/en not_active Abandoned
- 2015-04-27 RU RU2017130464A patent/RU2695443C2/ru active
- 2015-04-27 PL PL15719675T patent/PL3250600T3/pl unknown
- 2015-04-27 CN CN201580074799.1A patent/CN107206075A/zh active Pending
- 2015-04-27 PT PT157196759T patent/PT3250600T/pt unknown
- 2015-04-27 ES ES15719675T patent/ES2802982T3/es active Active
- 2015-04-27 EP EP20172402.8A patent/EP3744735A1/en active Pending
- 2015-04-27 LT LTEP15719675.9T patent/LT3250600T/lt unknown
- 2015-04-27 KR KR1020177024036A patent/KR102543877B1/ko active IP Right Grant
- 2015-04-27 WO PCT/EP2015/059095 patent/WO2016119909A1/en active Application Filing
- 2015-04-27 EP EP15719675.9A patent/EP3250600B1/en active Active
- 2015-04-27 DK DK15719675.9T patent/DK3250600T3/da active
-
2020
- 2020-06-26 HR HRP20201013TT patent/HRP20201013T1/hr unknown
- 2020-07-10 CY CY20201100635T patent/CY1123116T1/el unknown
-
2021
- 2021-06-29 US US17/361,393 patent/US11884737B2/en active Active
-
2022
- 2022-01-19 AU AU2022200347A patent/AU2022200347A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210324095A1 (en) | 2021-10-21 |
| GB201501613D0 (en) | 2015-03-18 |
| AU2015379642B2 (en) | 2021-11-04 |
| KR102543877B1 (ko) | 2023-06-14 |
| EP3250600A1 (en) | 2017-12-06 |
| RS60575B1 (sr) | 2020-08-31 |
| WO2016119909A1 (en) | 2016-08-04 |
| CY1123116T1 (el) | 2021-10-29 |
| US20180022812A1 (en) | 2018-01-25 |
| SI3250600T1 (sl) | 2020-09-30 |
| PT3250600T (pt) | 2020-06-17 |
| RU2017130464A3 (pl) | 2019-02-28 |
| LT3250600T (lt) | 2020-07-27 |
| NZ733454A (en) | 2023-12-22 |
| RU2017130464A (ru) | 2019-02-28 |
| ES2802982T3 (es) | 2021-01-22 |
| HRP20201013T1 (hr) | 2020-10-16 |
| EP3250600B1 (en) | 2020-05-06 |
| CA2975336C (en) | 2022-10-18 |
| RU2695443C2 (ru) | 2019-07-23 |
| CN107206075A (zh) | 2017-09-26 |
| CA2975336A1 (en) | 2016-08-04 |
| KR20170106476A (ko) | 2017-09-20 |
| HUE050024T2 (hu) | 2020-11-30 |
| EP3744735A1 (en) | 2020-12-02 |
| DK3250600T3 (da) | 2020-06-08 |
| AU2015379642A1 (en) | 2017-07-27 |
| AU2022200347A1 (en) | 2022-02-17 |
| US11884737B2 (en) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245331A1 (zh) | 基於李斯特菌的疫苗與抗ox40或抗gitr抗體的組合 | |
| IL285151A (en) | Methods for the treatment of fgf21-related disorders | |
| HK1247835A1 (zh) | 甲狀旁腺功能減退症的治療 | |
| HK1258062A1 (zh) | 給予惡拉戈利的方法 | |
| HK1256795A1 (zh) | 可用於治療自身免疫疾病的二吡唑基衍生物 | |
| HK1231386A1 (zh) | 免疫疾病的治療 | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| PL3250600T3 (pl) | Leczenie zaburzeń autoimmunologicznych przeciwciałami CD154 | |
| HK1254030A1 (zh) | 治療自身免疫病症和同種免疫病症的方法 | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| PL3129483T3 (pl) | Terapia skojarzona do leczenia chorób autoimmunologicznych | |
| EP3145931A4 (en) | Treatment of autoimmune disease | |
| HK1249866A1 (zh) | 用他塞利昔布進行治療的方法 | |
| SG11201708181RA (en) | Methods for the treatment of inflammatory disorders | |
| HK1255728A1 (zh) | 利用抗il-23a抗體的哮喘治療 | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| GB201521543D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201414023D0 (en) | Treatment of autoimmune diseases | |
| GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
| GB201509493D0 (en) | Therapeutic antibody | |
| GB201507113D0 (en) | Methods for the treatment of inflammatory disorders | |
| AU2014902194A0 (en) | Treatment of immune disorders | |
| GB201506419D0 (en) | Methods for the treatment of inflammatory disorders | |
| GB201506229D0 (en) | Methods For the Treatment Of Inflammatory Disorders |